Drug
ANTARA® (fenofibrate)
ANTARA® (fenofibrate) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
33%
Ph not_applicable
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (33.3%)
N/A2 (66.7%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions
NCT02306902
completednot_applicable
Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions
NCT02306889
completedphase_4
Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
NCT00246636
Clinical Trials (3)
Showing 3 of 3 trials
NCT02306902Not Applicable
Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions
NCT02306889Not Applicable
Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions
NCT00246636Phase 4
Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3